Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification. - Goddard J; Castle J; Southworth E; Fletcher A; Crosier S; Martin-Guerrero I; García-Ariza M; Navajas A; Masliah-Planchon J; Bourdeaut F; Dufour C; Ayrault O; et al. (Acta neuropathologica, 2023)